Provided by Tiger Trade Technology Pte. Ltd.

OCUMENSION-B

5.050
-0.170-3.26%
Volume:268.00K
Turnover:1.37M
Market Cap:4.12B
PE:-21.57
High:5.350
Open:5.150
Low:5.040
Close:5.220
52wk High:9.010
52wk Low:4.040
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:0.50
T/O Rate:0.03%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.234
ROE:-3.45%
ROA:-1.93%
PB:0.97
PE(LYR):-21.57
PS:3.76

Loading ...

US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy

Stock News
·
Sep 01

Ocumension Therapeutics' Application for Ocular Inflammation Drug Accepted in China

MT Newswires Live
·
Sep 01

Ocumension Therapeutics - Application for Dexamethasone Intraocular Suspension Accepted by Nmpa as Class 4 Chemical Drug

THOMSON REUTERS
·
Sep 01

Ocumension Says China Regulator Accepts Domestic Filing for Dexamethasone Eye Injection OT-502

Reuters
·
Sep 01

Ocumension Therapeutics - Acceptance of Application for Drug Registration of Domestically Produced Dexamethasone Intraocular Suspension

THOMSON REUTERS
·
Sep 01

Novartis Faces Dual Outcomes: CAR-T Halted After Three Deaths While MS Drug Shows Late-Stage Promise

Stock News
·
Sep 01

Trump Administration’s Medicaid Drug Pricing Deal Set to Stir Asian Pharma Stocks

Deep News
·
Sep 01

Ascletis Pharma-B Reports H1 Net Loss of RMB 320 Million, Widening by 263.5% Year-on-Year

Stock News
·
Aug 31

Ocumension Therapeutics Enrolls First Patient in Dry Eye Drug Study

MT Newswires Live
·
Aug 31

China's Angelalign H1 Revenue Rises on Higher Clear Aligner Case Volume

Reuters
·
Aug 31

Israel's BioLineRx Q2 Net Loss Widens on Higher R&D Expenses

Reuters
·
Aug 31

OCUMENSION Initiates Phase III Trial of First-in-Class Dry Eye Drug OT-202 with First Patient Enrolled in China

Bulletin Express
·
Aug 31

OCUMENSION-B's Dry Eye Candidate OT-202 Commences Late-Stage Dosing in China

Stock News
·
Aug 31

Ocumension Completes First Patient Enrollment in Phase III China Trial of Dry Eye Drug OT-202

Reuters
·
Aug 31

China's Rainmed Medical H1 Revenue Rises, Net Loss Narrows

Reuters
·
Aug 31

Hong Kong's Lee's Pharmaceutical H1 Profit Jumps on Higher-Margin Product Sales

Reuters
·
Aug 31

China's HeartCare Medical H1 Revenue Surges on Stroke Segment Growth

Reuters
·
Aug 31

Ocumension Therapeutics (SEHK:1477) Stock Growth Story Runs Into Funding Risk

Simply Wall St.
·
Aug 30

OCUMENSION-B (01477) reports 57.5M yuan adjusted net loss for the first half, narrowing by 46.74% year-on-year

Stock News
·
Aug 29

China's Ocumension Therapeutics H1 Revenue Surges on Higher Ophthalmic Product Sales

Reuters
·
Aug 28